Achilles Therapeutics plc (ACHL) Stock Analysis
DELISTED 2025
What happened to Achilles Therapeutics plc (ACHL) stock?
Achilles Therapeutics plc (ACHL) no longer trades on public markets. It was delisted in March 2025. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- March 2025
- Last recorded price (historical):
- $1.48 (last quote on record before the March 2025 delisting; historical, not a current quote)
Market cap $60.8M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Achilles Therapeutics plc (ACHL). Achilles Therapeutics plc is a clinical-stage immuno-oncology company focused on developing precision T cell therapies for solid tumors. Their personalized approach targets clonal neoantigens to provide individualized cancer treatments.
Last analyzed: Mar 16, 2026Dated analysis: the newest financial statements on file are 25 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
Achilles Therapeutics plc (ACHL) Healthcare & Pipeline Overview
Achilles Therapeutics plc ADR Information Sponsored
Achilles Therapeutics plc (ACHL) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy ACHL shares?
No. ACHL stopped trading on public markets in March 2025, so the shares are not available through a broker. Anything you see quoted for ACHL elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ACHL stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Achilles Therapeutics plc. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.